Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Shareholders held by Rexahn Pharmaceuticals, Inc. on June 14, 2018. The filing details the voting results for three proposals and the subsequent adjournment of the meeting regarding a fourth proposal. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and shareholder voting. It does not provide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Shareholders holding 23,977,553 shares (out of 31,744,439 outstanding) participated in the meeting. The results were as follows:
- Proposal 1 (Election of Directors): All five nominees (Charles Beever, Peter Brandt, Kwang Soo Cheong, Richard J. Rodgers, Peter Suzdak) were elected. Significant broker non-votes (12,466,158) were recorded for each nominee.
- Proposal 2 (Ratification of Auditors): The appointment of Baker Tilly Virchow Krause, LLP was ratified with 21,780,643 votes For, 1,721,662 Against, and 475,247 Abstain.
- Proposal 4 (Adjournment Authority): Approved to allow the meeting to adjourn and reconvene to solicit additional proxies for Proposal 3. Results: 17,268,785 For, 6,341,591 Against, 367,175 Abstain.
- Proposal 3 (Increase Authorized Shares): The proposal to increase authorized common stock from 50,000,000 to 100,000,000 failed to pass at this meeting. The meeting was adjourned to solicit additional proxies.
Outlook, Risks, and Unusual Items
Unusual Item/Action Required: The Annual Meeting was adjourned specifically regarding Proposal 3. The meeting is scheduled to reconvene on June 27, 2018, at 8:00 a.m. EDT at the Radisson Hotel in Rockville, Maryland, to vote on the amendment to the Certificate of Incorporation.
The filing contains no management commentary on financial outlook, risks, or contingencies beyond the procedural necessity of the adjournment.
Investor Verification Checklist
- Verify the outcome of the reconvened meeting on June 27, 2018, regarding the increase of authorized shares (Proposal 3).
- Confirm the final composition of the Board of Directors following the election of the five nominees.
- Review the Definitive Proxy Statement filed on April 23, 2018, for detailed background on the proposals.
- Note the discrepancy between the request metadata (Opus Genetics) and the filing registrant (Rexahn Pharmaceuticals).